Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 1 | 65 | or breastfeeding | 26 | |
| 2 | 2 | women of child bearing potential who are | 42 | or nursing lactating women | 20 |
| 3 | 20 | women who are | 4 | women | 14 |
| 4 | 18 | female of child bearing potential who is or has intention to be | 1 | women or nursing mothers | 6 |
| 5 | 24 | just prior to first vaccination within 21 days r n women of child bearing potential who are | 1 | 5 | |
| 6 | 38 | is a woman of child bearing potential wocbp who are | 1 | or breast feeding | 5 |
| 7 | 39 | women of child bearing potential must attest to not being | 1 | or nursing lactating women . | 5 |
| 8 | 44 | all women of child bearing potential wocbp shomcLd be instructed to contact the investigator immediately if they suspect they might be | 1 | or breastfeeding females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential | 2 |
| 9 | 47 | they must not be | 1 | or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant | 2 |
| 10 | 53 | patients who are | 1 | women or nursing mothers are not eligible for this trial patients of child bearing potential must use adequate contraception | 2 |
| 11 | 56 | patients that become | 1 | or nursing mothers | 2 |
| 12 | 64 | donor must not be | 1 | or nursing lactating | 2 |
| 13 | 69 | lactation or | 1 | or breast feeding women will not be entered on this study women of childbearing potential must obtain a pregnancy test child bearing potential is defined as having neither of the following r n > = 12 months of non therapy induced amenorrhea r n surgically sterile absence of ovaries and / or uterus | 1 |
| 14 | 70 | not be | 1 | or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant . | 1 |
| 15 | 79 | study drug must not be administered to | 1 | or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant . females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential | 1 |
| 16 | 119 | lactating / nursing or plan to become | 1 | or breast feeding patients or any patient with child bearing potential not using adequate contraception | 1 |
| 17 | 3 | NA | or breastfeeding women of child bearing potential are defined as all women except women who are post menopausal or who have had a hysterectomy postmenopausal will be defined as women over the age of 55 who have not had a menstrual period in at least 1 year | 1 | |
| 18 | 4 | NA | or lactating woman as evaluated by serum testing within 48 hours of administration of the first vaccine in women of child bearing potential | 1 | |
| 19 | 5 | NA | or breastfeeding . | 1 | |
| 20 | 6 | NA | or breastfeeding women with a positive pregnancy test at enrollment or prior to administration of vaccine | 1 | |
| 21 | 7 | NA | or breastfeeding r n women with a positive pregnancy test prior to administration of vaccine | 1 | |
| 22 | 8 | NA | or nursing | 1 | |
| 23 | 9 | NA | pregnancy testing will be at the discretion of the treating physician | 1 | |
| 24 | 10 | NA | or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant . females who have undergone surgical sterilization are not considered to be of childbearing potential | 1 | |
| 25 | 11 | NA | or breast feeding women women with child bearing potential must use effective measures to prevent pregnancy while receiving pegylated liposomal doxorubicin | 1 | |
| 26 | 12 | NA | or breast feeding . | 1 | |
| 27 | 13 | NA | or breastfeeding additionally | 1 | |
| 28 | 14 | NA | while on study protocol will be discontinued immediately | 1 | |
| 29 | 15 | NA | or breastfeeding . recipient exclusion criteria | 1 | |
| 30 | 16 | NA | women and women of child bearing potential are eligible for participation in this study | 1 | |
| 31 | 17 | NA | women of child bearing potential will be excluded | 1 | |
| 32 | 19 | NA | or become pregnant during the study if the participant is a woman of child bearing potential i . e . | 1 | |
| 33 | 21 | NA | and nursing mothers are excluded from this study . | 1 | |
| 34 | 22 | NA | or nursing mothers are excluded | 1 | |
| 35 | 23 | NA | women are excluded from this study nursing mothers shomcLd stop breastfeeding to be eligible | 1 | |
| 36 | 25 | NA | women are excluded from this study in nursing mothers | 1 | |
| 37 | 26 | NA | women and breastfeeding mothers are excluded | 1 | |
| 38 | 27 | NA | and nursing mothers are excluded from this study | 1 | |
| 39 | 28 | NA | women and nursing mothers | 1 | |
| 40 | 29 | NA | women are excluded from this study breastfeeding shomcLd be discontinued by nursing mothers who agree to participate in the study | 1 | |
| 41 | 30 | NA | women / lactating mothers | 1 | |
| 42 | 31 | NA | women or nursing mothers are not eligible for this trial . patients of child bearing potential must use adequate contraception contraceptive pill | 1 | |
| 43 | 32 | NA | or nursing lactating women additional exclusion criteria for lxh254 in combination with pdr001 | 1 | |
| 44 | 33 | NA | or nursing lactating women breastfeeding shomcLd be discontinued | 1 | |
| 45 | 34 | NA | or nursing lactating . | 1 |